


PHARMACEUTICAL 2021

Foghorn Therapeutics Inc. Rank 166 of 409









PHARMACEUTICAL 2021



Foghorn Therapeutics Inc. Rank 166 of 409

The relative strengths and weaknesses of Foghorn Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Foghorn Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Foghorn Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is -65%, being 290% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	190,687
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,846
Liabilities, Non-Current	90,561
Other Assets	45,379
Other Compr. Net Income	-7.0
Other Expenses	0
Other Liabilities	0
Other Net Income	-269
Property and Equipment	19,528
Research and Development	57,715
Revenues	430
Selling, General and Administrative Expense	11,246

Output Variable	Value in 1000 USD
Assets	255,594
Liabilities	109,407
Expenses	68,961
Stockholders Equity	146,187
Net Income	-68,800
Comprehensive Net Income	-68,804
Economic Capital Ratio	-65%

